Although several gene therapy approaches based on NPY and Y2R, have been investigated in pre-clinical models of acquired epilepsy (Noè et al, 2008, 2010; Nikitidou Ledri et al, 2016; Szczygieł et al, 2020b), so far, only one study has been conducted in a genetic model, specifically a model of absence seizures (Powell et al, 2018) in which NPY, delivered in the thalamus and somatosensory cortex via AAV-mediated transduction, proved effective in suppressing absence-like seizures. This evidence concerns the gene NPY and juvenile absence epilepsy.